Journal
CLINICAL LIPIDOLOGY
Volume 5, Issue 2, Pages 209-219Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/CLP.10.11
Keywords
aspirin; cardiovascular disease; cyclooxygenase; platelets; thromboxane A(2)
Categories
Funding
- NIH [NIH/NHLBI RO1 HL066233]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066233] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Thromboxane A(2) (TXA(2)), the primary product of COX-1-dependent metabolism of arachidonic acid, mediates its biological actions through the TXA(2) receptor, termed the TP. Irreversible inhibition of platelet COX-I1 derived TXA2 with low-dose aspirin affords protection against primary and secondary vascular thrombotic events, underscoring the central role of TXA(2) as a platelet agonist in cardiovascular disease. The limitations associated with aspirin use include significant gastrointestinal toxicity, bleeding complications, potential inter-individual response variability and poor efficacy in some disease states. This, together with the broad role of TXA(2) in cardiovascular disease beyond the platelet, has refocused interest towards additional TXA(2)-associated drug targets, in particular TXA(2) synthase and the TP. The superiority of these agents over low-dose aspirin, in terms of clinical efficacy, tolerability and commercial viability, remain open questions that are the focus of ongoing research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available